Cargando…

Formulation, Development and Evaluation of Budesonide Oral Nano-sponges Using DOE Approach: In Vivo Evidences

Purpose: The prevalent types of idiopathic inflammatory bowel disease are ulcerative colitis (UC) and Crohn’s disease, which affects a large number of populations. Budesonide (BUD) is a glucocorticoid with potent anti-inflammatory activity but low systemic efficacy because of high receptor affinity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salunke, Amarjit, Upmanyu, Neeraj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Tabriz University of Medical Sciences 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046401/ https://www.ncbi.nlm.nih.gov/pubmed/33880350 http://dx.doi.org/10.34172/apb.2021.041

Ejemplares similares

In vitro - in vivo - in silico approach in the development of inhaled drug products: Nanocrystal-based formulations with budesonide as a model drug
por: Shi, Changzhi, et al.
Publicado: (2021)

Comparison of Aerosol Formulations of Formoterol Fumarate and Budesonide
por: Nirale, N. M., et al.
Publicado: (2011)

Mucoadhesive Budesonide Formulation for the Treatment of Eosinophilic Esophagitis
por: Casiraghi, Antonella, et al.
Publicado: (2020)

Formulation and evaluation of sustained release enteric-coated pellets of budesonide for intestinal delivery
por: Raval, Mihir K, et al.
Publicado: (2013)

Rectal budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: efficacy, tolerance, and treatment approach
por: Christophi, George P, et al.
Publicado: (2016)

Validated gradient stability indicating HPLC method for determining Diltiazem Hydrochloride and related substances in bulk drug and novel tablet formulation
por: Chatpalliwar, Vivekanand A., et al.
Publicado: (2012)

Evaluation of a Nanodispersion Formulation Prepared through Microfluidic Reactors for Pulmonary Delivery of Budesonide Using Nebulizers
por: Ali, Hany SM, et al.
Publicado: (2014)

Inhalable Nano-Dimpled Microspheres Containing Budesonide-PLGA for Improved Aerodynamic Performance
por: Han, Chang-Soo, et al.
Publicado: (2022)

Formulation and optimization of solid lipid nanoparticle formulation for pulmonary delivery of budesonide using Taguchi and Box-Behnken design
por: Emami, J., et al.
Publicado: (2015)

Oral Hairy Leukoplakia Related to Orodispersible Budesonide Use
por: McNeice, Andrew, et al.
Publicado: (2020)

Exogenous Surfactant as a Pulmonary Delivery Vehicle for Budesonide In Vivo
por: Baer, Brandon, et al.
Publicado: (2020)

A Pharmacokinetic Bridging Study to Compare Systemic Exposure to Budesonide between Budesonide Oral Suspension and ENTOCORT EC in Healthy Individuals
por: Song, Ivy H., et al.
Publicado: (2020)

Assay of Desmopressin Acetate in Nasal Spray: Development of Validated Pre Column HPLC-Fluorescence Method
por: Upmanyu, Neeraj, et al.
Publicado: (2017)

Simvastatin Solid Lipid Nanoparticles for Oral Delivery: Formulation Development and In vivo Evaluation
por: Padhye, S. G., et al.
Publicado: (2013)

Pharmacokinetics of Budesonide Oral Suspension in Children and Adolescents With Eosinophilic Esophagitis
por: Gupta, Sandeep K., et al.
Publicado: (2022)

Rehydrated sterically stabilized phospholipid nanomicelles of budesonide for nebulization: physicochemical characterization and in vitro, in vivo evaluations
por: Sahib, Mohanad Naji, et al.
Publicado: (2011)

Budesonide-Loaded Guar Gum Microspheres for Colon Delivery: Preparation, Characterization and in Vitro/in Vivo Evaluation
por: Liu, Ye, et al.
Publicado: (2015)

Development of novel budesonide pellets based on CODES(TM) technology: In vitro/in vivo evaluation in induced colitis in rats
por: Varshosaz, J., et al.
Publicado: (2011)

Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma
por: Morice, A H, et al.
Publicado: (2007)

Protocol: Influence of Budesonide and Budesonide/Formoterol on Asthma Control in Smoking Asthmatic Adults
por: Boulet, Louis-Philippe, et al.
Publicado: (2010)

Resolution of Anastomotic Ulceration and Profound Bleeding by Endoscopic Cauterization and Oral Budesonide
por: Xi, Dong, et al.
Publicado: (2023)

Development and Evaluation of Inhalational Liposomal System of Budesonide for Better Management of Asthma
por: Parmar, J. J., et al.
Publicado: (2010)

Comment on Casiraghi et al. “Mucoadhesive Budesonide Formulation for the Treatment of Eosinophilic Esophagitis” 2020, 12, 211
por: Zur, Eyal
Publicado: (2020)

Comparison of HPMC Inhalation-Grade Capsules and Their Effect on Aerosol Performance Using Budesonide and Rifampicin DPI Formulations
por: Ding, Li, et al.
Publicado: (2022)

Assessment by HPLC of the degradation behavior of acitretin under hydrolytic, oxidative, photolytic and thermal stress conditions
por: Porwal, Pawan K., et al.
Publicado: (2014)

Saponin Micelles Lead to High Mucosal Permeation and In Vivo Efficacy of Solubilized Budesonide
por: Nakowitsch, Sabine, et al.
Publicado: (2020)

Etoposide Amorphous Nanopowder for Improved Oral Bioavailability: Formulation Development, Optimization, in vitro and in vivo Evaluation
por: Wang, Yue, et al.
Publicado: (2020)

Development and validation of a rapid HPLC method for simultaneous analysis of budesonide and its novel synthesized hemiesters in colon specific formulations
por: Varshosaz, J., et al.
Publicado: (2011)

Anti-inflammatory and antinociceptive evaluation of newly synthesized 4-(substituted ethanoyl) amino-3-mercapto-5-(4-methoxy) phenyl-1,2,4-triazoles
por: Upmanyu, Neeraj, et al.
Publicado: (2011)

Dasatinib-Loaded Topical Nano-Emulgel for Rheumatoid Arthritis: Formulation Design and Optimization by QbD, In Vitro, Ex Vivo, and In Vivo Evaluation
por: Donthi, Mahipal Reddy, et al.
Publicado: (2023)

Eosinophilic gastroenteritis with gastric and small bowel involvement: successful treatment with oral budesonide
por: Alsayegh, Mohammad, et al.
Publicado: (2012)

Oral liposomal delivery of an activatable budesonide prodrug reduces colitis in experimental mice
por: Xian, Shiyun, et al.
Publicado: (2023)

Randomised, crossover clinical trial, in healthy volunteers, to compare the systemic availability of two topical intranasal budesonide formulations
por: Algorta, Jaime, et al.
Publicado: (2008)

A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis
por: Miehlke, Stephan, et al.
Publicado: (2016)

Reply to “Comment on Casiraghi et al. ‘Mucoadhesive Budesonide Formulation for the Treatment of Eosinophilic Esophagitis’ 2020, 12, 211”
por: Casiraghi, Antonella, et al.
Publicado: (2020)

A New Viscous Budesonide Formulation for the Treatment of Eosinophilic Esophagitis in Children: A Preliminary Experience and Review of the Literature
por: Warzecha, Joanna, et al.
Publicado: (2022)

Nanoparticle formulation by Büchi B-90 Nano Spray Dryer for oral mucoadhesion
por: Harsha, Sree N, et al.
Publicado: (2015)

Bioactive Apigenin loaded oral nano bilosomes: Formulation optimization to preclinical assessment
por: Zafar, Ameeduzzafar, et al.
Publicado: (2021)

Budesonide and fluticasone and adrenal suppression
por: Fouda, Mona A, et al.
Publicado: (2012)

Eosinophilic cholangitis treatment with budesonide
por: De Roza, Marianne Anastasia, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_g9rrjitc9hq9rbv38bdcjb43ih